Stereotaxis, Inc.(STXS)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #2,804 of 2,962 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
STXS Stock Analysis & AI Quality Score
Data updated 2026-09-11AI stock analysis and institutional research for Stereotaxis, Inc. (STXS), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores STXS at 18.7/100 on a 32-signal composite quality model, placing it at rank #2,804 of 2,962 stocks — the bottom half of the AI-ranked universe. Areas of concern include balance sheet strength (4.1) and revenue scale (5.0), which score below median versus the broader universe. Shareholder dilution risk is elevated at 6.3/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Stereotaxis, Inc. reports quarterly revenue of $7.7M, net income of $-4.5M, an operating margin of -59.6%. Top institutional holders of STXS by reported 13-F value include DAFNA Capital Management, BlackRock, Lagoda Investment Management, L.P., based on the most recent SEC filings. STXS trades on the NYSE exchange and files with the SEC under CIK 1289340. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate STXS daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Stereotaxis, Inc. directly from SEC EDGAR. Stereotaxis, Inc.'s 13F Pro composite quality score has ranged between 10 and 25 since 2021, currently 18.7 — a stable long-term trajectory across 68 quarterly and live scoring snapshots.
Revenue
Q2 2026
$7.7M
Net Income
Q2 2026
$-4.5M
Free Cash Flow
Q2 2026
$-3.7M
Operating Margin
Q2 2026
-59.6%
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
+20.3% YoYNet Income
+10.0% YoYOperating Income
+10.6% YoYEPS (Diluted)
+16.7% YoYTotal Assets
+11.8% YoYTotal Debt
Op. Cash Flow
-61.1% YoYFree Cash Flow
-61.5% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $32.4M +20.3% | $26.9M +0.5% | $26.8M -4.9% | $28.1M -19.6% | $35.0M +31.5% | $26.6M |
| Net Income | $-21.6M +10.0% | $-24.0M -16.1% | $-20.7M -13.2% | $-18.3M -70.7% | $-10.7M -61.2% | $-6.6M |
| Operating Income | $-22.1M +10.6% | $-24.7M -13.3% | $-21.8M -16.3% | $-18.8M -45.7% | $-12.9M -92.0% | $-6.7M |
| EPS (Diluted) | $-0.25 +16.7% | $-0.30 -11.1% | $-0.27 -3.8% | $-0.26 -62.5% | $-0.16 -45.5% | $-0.11 |
| Total Assets | $52.3M +11.8% | $46.7M +11.5% | $41.9M -21.5% | $53.4M -12.4% | $61.0M +10.0% | $55.5M |
| Total Debt | — | — | — | — | — | $2.2M |
| Operating Cash Flow | $-13.7M -61.1% | $-8.5M +7.0% | $-9.1M -8.6% | $-8.4M -185.6% | $-2.9M +16.1% | $-3.5M |
| Free Cash Flow | $-13.8M -61.5% | $-8.5M +10.2% | $-9.5M +11.9% | $-10.8M -148.5% | $-4.3M -21.2% | $-3.6M |
Get alerted when STXS's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Stereotaxis, Inc. including:
Top Institutional Holders of STXS
DAFNA Capital Management LLC
$23.5M13,680,554 shBlackRock, Inc.
$7.6M4,396,835 shLagoda Investment Management, L.P.
$7.1M4,122,600 shVANGUARD CAPITAL MANAGEMENT LLC
$5.2M3,044,820 shGEODE CAPITAL MANAGEMENT, LLC
$3.3M1,895,243 shESSEX INVESTMENT MANAGEMENT CO LLC
$2.6M1,521,966 shArchon Capital Management LLC
$2.1M1,226,044 shWarberg Asset Management LLC
$1.9M1,108,889 shSTATE STREET CORP
$1.6M916,780 shAlphaCentric Advisors LLC
$1.0M600,000 sh
| Fund | Value | Shares |
|---|---|---|
| DAFNA Capital Management LLC | $23.5M | 13,680,554 |
| BlackRock, Inc. | $7.6M | 4,396,835 |
| Lagoda Investment Management, L.P. | $7.1M | 4,122,600 |
| VANGUARD CAPITAL MANAGEMENT LLC | $5.2M | 3,044,820 |
| GEODE CAPITAL MANAGEMENT, LLC | $3.3M | 1,895,243 |
| ESSEX INVESTMENT MANAGEMENT CO LLC | $2.6M | 1,521,966 |
| Archon Capital Management LLC | $2.1M | 1,226,044 |
| Warberg Asset Management LLC | $1.9M | 1,108,889 |
| STATE STREET CORP | $1.6M | 916,780 |
| AlphaCentric Advisors LLC | $1.0M | 600,000 |
Companies Similar to STXS
Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.
ADC Therapeutics SA
Apyx Medical Corp
Outset Medical, Inc.
Verrica Pharmaceuticals Inc.
SS Innovations International, Inc.
Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.
More Healthcare Companies
View all Healthcare →Put STXS on your watchlist
Track score changes the day Stereotaxis, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is STXS a good stock to buy?
13F Pro's AI-powered analysis of Stereotaxis, Inc. (STXS) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for STXS are available on the STXS stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. STXS is classified as a small company.
Which hedge funds own STXS?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling STXS. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Stereotaxis, Inc.'s investment landscape.